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DE
ASUMMARY
Hepatic steatosis is generally thought to develop via
peripheral mechanisms associated with obesity. We
show that chronic central infusion of leptin sup-
presses hepatic lipogenic gene expression and re-
duces triglyceride content via stimulation of hepatic
sympathetic activity. This leptin function is indepen-
dent of feeding and body weight but requires phos-
phatidylinositol 3-kinase (PI3K) signaling. Attenua-
tion of leptin-induced PI3K signaling, brought about
by transgenic expression of phosphatase and tensin
homolog (PTEN) in leptin receptor neurons, leads to
decreased hepatic sympathetic tone and increased
triglyceride levels without affecting adiposity or
hepatic insulin signaling. Central leptin’s effects on
hepatic norepinephrine levels and triglyceride con-
tent are blunted in these mutant mice. Simultaneous
downregulation of PI3K and signal transducer and
activator of transcription-3 (Stat3) in leptin receptor
neurons does not exacerbate obesity but causes
more severe hepatic steatosis. Together, our results
indicate that central cellular leptin resistance in PI3K
signaling manifests as hepatic steatosis without
causing obesity.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of
liver dysfunction and affects over 30% of the Western pop-
ulation (Browning et al., 2004). NAFLD is closely associated
with obesity and insulin resistance and is commonly attributed
to clinical features of these conditions, such as increased non-
esterified fatty acids (NEFA) flux and hyperinsulemia-induced
lipogenesis (Brown and Goldstein, 2008; Postic and Girard,
2008). Leptin, an adipocyte-secreted hormone, conveys the
body’s energy status to the brain by circulating at levels pro-
portional to body fat mass. Leptin activates multiple signaling
RE
TRCell Mpathways, notably Stat3 and PI3K, in neurons that express
the long form of the leptin receptor (LepRb; Myers et al.,
2008). Mice with defective leptin-mediated Stat3 signaling
exhibit hyperphagia and obesity, thus demonstrating the im-
portance of this pathway in feeding and energy balance (Bates
et al., 2003; Piper et al., 2008). In most common forms of
obesity, such as diet-induced obesity, body adiposity is
elevated despite the presence of hyperleptinemia, thus indi-
cating impaired leptin function. When directly administered
into the brain of obese animals, leptin fails to activate its sig-
naling pathways in hypothalamic neurons, a hallmark feature
of central cellular leptin resistance (Myers et al., 2010). Impor-
tantly, impairment of the leptin-induced Stat3 and PI3K sig-
naling pathways can be uncoupled temporally upon short-
term exposure to high-fat feeding (Metlakunta et al., 2008),
suggesting differential regulation by distinct mechanisms dur-
ing diet-induced obesity.
Leptin deficiency in humans and rodents leads to obesity,
insulin resistance, and hepatic steatosis (Farooqi and O’Rahilly,
2005). Diet-induced obesity, another leptin insufficient state
resulting from leptin resistance, is also accompanied by hepatic
steatosis. Chronic leptin administration inhibits liver stearoyl-
CoA desaturase 1 (Scd1) gene expression compared to pair-
fed animals, and deletion of Scd1 in leptin-deficient mice re-
duces feeding, body weight, and hepatic steatosis (Cohen
et al., 2002). In addition, chronic intracerebroventricular (i.c.v.)
injection of leptin causes downregulation of genes encoding
Scd1, acetyl-coenzyme A-carboxylase (Acc), and fatty acid
synthase (Fas) in the liver when compared with vehicle-infused
pair-fed rats (Gallardo et al., 2007), suggesting that leptin acts
in the brain to suppress liver lipogenic gene expression via
a mechanism that is independent of feeding. Here, we show
that chronic central administration of leptin activates the sym-
pathetic nervous system to suppress expression of lipogenic
genes in the liver. Furthermore, attenuation of leptin-mediated
PI3K signaling in LepRb neurons causes decreased sympathetic
tone in the liver and increased hepatic steatosis without affecting
body adiposity. Collectively, these results suggest that central
cellular leptin resistance, mediated by the impairment of leptin-
induced PI3K signaling, can manifest as hepatic steatosis in
the absence of obesity.
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Central Leptin Decreases Hepatic Triglycerides
Independent of Food Intake
Adult leptin-deficient ob/ob mice have severe obesity and
hepatic steatosis. Despite similar body weights, we observed
that 2-week-old preobese ob/ob mice had heavier livers and
higher liver triglyceride content than control littermates at the
same age, suggesting that leptin suppresses liver triglyceride
content independent of its actions on adiposity (Figures
S1A–S1D available online). Furthermore, plasma leptin concen-
trations negatively correlate with liver triglyceride content (R2 =
0.80, p < 0.001) in wild-type mice that were fed, fasted or refed
(Figure S1E). To assess whether leptin acts in the brain to reduce
liver triglyceride content, we continuously infused leptin into the
brain of adult wild-type mice for 7 days using osmotic mini-
pumps. In this particular experiment, body weight and food
intake was not altered in the leptin-treatment group compared
to the vehicle treatment group, negating the need for pair-
feeding (Figures 1A and 1B). Fat depot weights and plasma leptin
levels did not differ between the vehicle and leptin groups
(Figures 1C and 1D). Liver triglyceride levels were significantly
reduced, and this was associated with decreased hepatic
mRNA expression of Acc, Fas, and Scd1 (Figures 1E and 1F)
but not the mRNA expression of liver pyruvate kinase (L-Pk),
sterol regulatory element-binding protein 1c (Srebp1c), or
carbohydrate-responsive element-binding protein (Chrepb). In
agreement with the mRNA data, the liver activity of FAS (Fig-
ure 1G) and the protein levels of ACC (Figure 1H) were also lower
after leptin infusion, with the levels of phosphorylated-ACC
appropriate for total levels. Basal AKT phosphorylationwas unal-
tered by central leptin infusion (Figure S2A). Blood glucose and
plasma insulin concentrations were lower with leptin treatment
(Figures 1I and1J), although leptin’s suppressive effect on liver
Scd1 expression is independent of circulating insulin levels or
hepatic insulin action (Biddinger et al., 2006). Collectively, these
data show that chronic central leptin action can suppress
hepatic triglyceride content via a mechanism that is independent
of food intake and body weight.
Central Leptin Infusion Increases Hepatic Sympathetic
Activity
Leptin has been shown to activate the sympathetic nervous
system of humans, primates, and rodents (Buettner et al.,
2008; Rosenbaumet al., 2005; Satoh et al., 1999; Tang-Christen-
sen et al., 1999). Therefore, we investigated whether the sympa-
thetic nervous system was activated in mice that had received
chronic leptin infusion into the brain. Plasma and liver norepi-
nephrine (NE) levels were elevated in leptin-treated mice, indi-
cating activation of the sympathetic nervous system (Figures
1K and 1L). Furthermore, the mRNA levels of Acc, Fas, and
Scd1 all showed significant inverse correlations with liver NE
content (Figures 1M–1O).
To demonstrate that leptin can act within the brain to stimulate
hepatic sympathetic activity, we examined NE turnover in mice
that had received an i.c.v. injection of vehicle or leptin into the
lateral ventricle. Determination of the NE turnover rate utilizes
administration of tyrosine hydroxylase inhibitor a-MPT, which
causes a time-dependent decline in liver NE levels (Figures 2A
RE
TR792 Cell Metabolism 14, 791–803, December 7, 2011 ª2011 Elsevierand 2B; Brodie et al., 1966; Spector et al., 1965). Mice were
weight-matched prior to the injections (Figure 2C). Mice that
had received an i.c.v. injection of leptin showed lower liver NE
concentrations at the end of the study (Figure 2D), demon-
strating increased liver NE turnover (Figure 2E). These data
show that leptin acts centrally to increase liver sympathetic
nervous activity.
We further examined lipogenic gene expression in the livers
of the a-MPT/i.c.v. vehicle- or a-MPT/i.c.v. leptin-treated mice
to determine whether leptin would inhibit the expression of
these genes in the absence of NE biosynthesis. Under these
experimental conditions, i.c.v. leptin administration led to an
increase in liver Acc, Fas, and Scd1 mRNA expression; L-Pk,
Chrebp, and Srebp1c were unaffected (Figure 2F). The en-
hanced expression of liver lipogenic genes agrees with the
greater decline of NE in the liver of a-MPT/i.c.v. leptin-treated
mice, suggesting that prevailing NE levels may determine the
levels of gene expression. The loss of leptin’s suppressive
effects on hepatic lipogenic gene expression upon block-
ade of NE biosynthesis suggests that leptin regulates liver
lipid metabolism via activation of the sympathetic nervous
system.
Norepinephrine Inhibits De Novo Lipogenic Gene
Expression in Liver Explants
To demonstrate whether NE directly regulates lipogenic gene
expression in the liver, we bathed liver explants in various con-
centrations (0–10mM) of NE. NE treatment caused a dose-
dependent decrease in Acc, Fas, and Scd1 mRNA expression
(Figure 2G), indicating direct NE action in the liver.
Inhibition of Central PI3K Activity Blocks Leptin’s
Effects on Liver Fat Content
Leptin fails to activate hypothalamic PI3K activity in the early
stages of diet-induced obesity before defects in leptin-induced
Stat3 signaling can be detected (Metlakunta et al., 2008).
Because hepatic steatosis develops after short-term high-fat
feeding before any significant weight gain (Samuel et al., 2004),
we investigated whether leptin-mediated PI3K signaling plays
a role in reducing liver triglyceride levels. We infused PI3K inhib-
itor LY294002 into the brain at a dose that by itself did not affect
body weight, food intake, fat depot weight, liver triglyceride
levels, or de novo lipogenic gene expression (Figures 3C-3L).
Seven days of leptin treatment increased phosphorylated
AKT levels in the brain without altering total AKT protein levels
(Figures 3A and 3B), an effect that was prevented by
LY294002 coinfusion. Although chronic infusion of LY294002
into the brain did not affect leptin’s effects on body weight,
food intake, or fat mass, it significantly blunted the effects of
leptin on liver triglyceride levels, the mRNA expression of Acc,
Fas, and Scd1, and FAS enzymatic activity (Figures 3C-3K).
These data suggest that leptin’s inhibitory effect on liver triglyc-
eride content requires functional PI3K signaling.
Like leptin, insulin signals through the PI3K pathway, and an
acute injection of insulin into the brain also reduces feeding
and body weight. However, recent studies have shown that
chronic infusion of insulin into the brain increases fat mass
without apparent effects on feeding via inhibition of sympathetic
nervous system outflow (Koch et al., 2008; Scherer et al., 2011).
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Figure 1. I.c.v. Administration of Leptin Causes Increased Liver Norepinephrine Content and Reduced Liver Triglyceride Levels Independent
of Feeding and Adiposity
(A–L) Mice were implanted with cannulae into the lateral ventricle attached to osmotic minipumps containing vehicle (aCSF, n = 5), or leptin (lot AFP1197,
4 mg/day, n = 4). Body weight (A), food intake (B), terminal fat depot weight (C), plasma leptin (D), liver triglyceride content (E), hepatic mRNA expression of Acc,
Fas, Scd1, L-Pk, Srebp1c, andChrebp (F), liver FAS activity (G), liver total and phosphorylated ACC protein levels (H), blood glucose (I), plasma insulin (J), plasma
(K), and liver NE (L) levels at day 7.
(M–O) Correlation between liver Acc (M), Fas (N), and Scd1 (O) mRNA and liver NE content.
Error bars represent the mean ± SEM. *p < 0.05, **p < 0.01 versus vehicle.
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DBecause insulin can act directly on hepatocytes to stimulate lipo-
genesis, we examined whether chronic insulin infusion into the
brain would also alter liver triglyceride levels. Infusion of insulin
into the brain for 7 days did not alter body weight or food intake,Cell Mbut significantly increased white adipose mass and liver triglyc-
eride content (Figures S2B–S2E). These results indicate that
central leptin and insulin play distinct roles in regulation of liver
lipid levels.etabolism 14, 791–803, December 7, 2011 ª2011 Elsevier Inc. 793
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Figure 2. Central Leptin Administration
Increases Hepatic Sympathetic Tone and
Leptin’s Suppressive Effects on Hepatic
Lipogenic Gene Expression Are Lost upon
Blockade of Norepinephrine Biosynthesis
(A) Liver NE levels after a-MPT treatment (n =
6/time point).
(B) Experimental timeline.
(C) Body weights prior to i.p./i.c.v. treatment (n =
6/group).
(D) Liver NE content at the end of the study.
(E) Liver NE turnover.
(F) Liver Acc, Fas, Scd1, L-Pk, Chrebp, and
Srebp1c mRNA expression.
(G) Liver explant mRNA expression of Acc, Fas,
and Scd1 after in vitro exposure to NE (n =
4/group).
Error bars represent the mean ± SEM. *p < 0.05,
**p < 0.01 versus vehicle or no drug.
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Signaling in LepRb-Expressing Cells
We next sought to determine if downregulation of leptin-induced
PI3K signaling contributes to hepatic steatosis or other meta-
bolic abnormalities. We chose to overexpress PTEN, a phos-
phatase that reverses PI3K kinase activity in LepRb cells, so
that specific attenuation of PI3K occurred only in direct leptin
targets. This strategy is distinct from approaches that delete
certain PI3K subunits because these often alter expression of794 Cell Metabolism 14, 791–803, December 7, 2011 ª2011 Elsevier Inc.nontargeted isoforms causing compen-
satory changes in kinase activities (Van-
haesebroeck et al., 2005).
Using a Cre-lox transgenic strategy
described previously (Reed et al., 2010),
we generated transgenic mice carrying
a Floxed-Stop-Tg.Pten allele such that
exogenousPtenwould only be expressed
in Cre-positive cells under the control of
the constitutively-active CMV promoter
(Figure 4A). We first crossed Floxed-
Stop-Tg.Pten with Tg.Nestin-Cre mice
to generate mutants (Nestin-Pten-OE).
Thus, Tg.Pten would be expressed in
the entire brain, making quantitative as-
says possible. Pten mRNA expression in
Nestin-Pten-OE mutants was elevated
1.8-fold in the Cre-positive brain but not
in the Cre-negative liver (Figure 4B). A
similar increase in PTEN protein expres-
sion was observed in the Nestin-Pten-
OE hypothalamus (Figure 4C). Phosphor-
ylation of AKT at threonine-308, a critical
site for AKT activation byPI3K, decreased
by 50%,whereas phosphorylation of ERK
was not affected (Figure 4C). Nestin-
Pten-OEmice exhibited impaired somatic
growth, increased adiposity, and glucose
intolerance compared with the Nestin-
Cre transgenic mice (Figure S3). These
Tphenotypes recapitulate those in mice carrying a germline
kinase-dead mutation of the PI3K catalytic subunit that also
results in a 50% loss of PI3K activity (Foukas et al., 2006).
We next crossed Floxed-Stop-Tg.Pten with Tg.LepRb-Cre
mice (Leshan et al., 2006) such that Tg.Ptenwould be expressed
in LepRb-expressing cells only (LepRb-Pten-OEmice). To deter-
mine whether downregulation of PI3K signaling would also occur
in the livers as well as the brains of these mutant mice, we exam-
ined Cre-mediated recombination in these tissues because
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Figure 3. PI3K Signaling Is Required for Regulation of Hepatic Norepinephrine Levels, Lipogenic Gene Expression and Liver Triglyceride
Content by Leptin
(A–K) Mice (n = 5/group) were implanted with canulae into the lateral ventricle attached to minipumps delivering vehicle (Veh), LY294002 (LY), leptin (Lep, lot
AFP1629), or LY and leptin together (LY+Lep) for 7 days. This experiment was distinct from the previous experiments in the composition of the vehicle and the lot
of leptin utilized, which may account for experiment-to-experiment variations. Terminal brain (A) phosphorylated AKT (pAKTthr308) and total AKT protein levels (B).
Body weight (C) and food intake(D) at day 7. Terminal fat depot weight (E) and liver triglyceride (F) levels, NE content (G), Acc (H), Scd1 (I), FasmRNA expression
(J), and FAS enzyme activity (K).
Error bars represent the mean ± SEM. **p < 0.01, comparison as denoted, n.s. = nonsignificant, #p < 0.05, ##p < 0.01 versus Veh and LY groups.
Cell Metabolism
Central Leptin Resistance and Hepatic Steatosis
RE
TR
AC
TE
Dexpression of Tg.Pten is Cre-dependent. Tg.LepRb-Cre mice
were crossed with a Cre-activatable LacZ reporter (R26R;
[Soriano, 1999]) such that lacZ expression marked cells withCell MCre recombinase activity. Although a strong LacZ signal was
observed in the hypothalamus of LepRb-Cre/R26R mice, we
observed no LacZ signal in hepatocytes (Figure S4A). To ruleetabolism 14, 791–803, December 7, 2011 ª2011 Elsevier Inc. 795
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Figure 4. Generation and Characterization of Transgenic Mice to Down-Regulate PI3K Signaling in LepRb Neurons
(A) Diagrammatic representation of the Floxed-Stop-Tg.Pten construct.
(B) Total (endogenous and transgenic) Pten mRNA expression in the hypothalamus or liver (16-week-old mice, n = 4–5/group).
(C) Western blot detection and quantification of hypothalamic PTEN, phosphorylated AKT (pAKT) and ERK (pERK), and total AKT and ERK protein expression in
18-day-old mice (n = 3–4/group).
(D) Representative western blot images and quantification of hypothalamic phosphorylated AKT (pAKTThr308) or STAT3 (pSTAT3) 45 min after i.p. injection with
either saline (n = 5/group) or leptin (n = 6/group) in 12-week-old mice.
Error bars represent the mean ± SEM. **p < 0.01 versus control.
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R
C
EDout sporadic recombination events, liver DNA from all mice
included in this study was screened for recombination of the
Floxed-Stop-Tg.Pten allele; all were negative (Figure S4B). This
result indicates that Tg.Pten was not expressed in the hepato-
cytes of the mutant animals.
Attenuated LepRbNeuron PI3K Signaling Does Not Alter
Hypothalamic Neuron Morphology
Changes in PI3K activity could potentially affect cell growth and
differentiation, which could alter neuronal functions independent
of dynamic regulation by metabolic signals. Thus, we examined
morphologic characteristics of proopiomelanocortin (Pomc) neu-
R
796 Cell Metabolism 14, 791–803, December 7, 2011 ª2011 Elsevierrons in LepRb-Pten-OEmicebecause themajority express LepRb
(Baskin et al., 1999) and, hence, Tg.Pten. Projection patterns,
Pomc cell number, and cell size were similar in control and
mutants, suggesting that attenuated PI3K signaling does not
cause developmental abnormalities in these neurons (Figure S5).
PTEN Overexpression in LepRb Neurons Abolishes
Leptin’s Ability to Activate Hypothalamic PI3K Signaling
To evaluate the ability of leptin to signal in the mutant animals,
leptin-induced hypothalamic Stat3 and PI3K signaling was ex-
amined by Western blot analysis in controls and LepRb-Pten-
OE mice. While leptin treatment induced phosphorylation ofInc.
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Figure 5. Attenuation of PI3K Signaling in LepRb Neurons Promotes Hepatic Steatosis Independent of Leptin-Mediated STAT3 Signaling
(A–I) Unless stated, measurements were made in 24-week-old mice (n = 6–14/group) under ad libitum chow-fed conditions. Comparison of LepRb-Pten-OE and
control littermates in body weight (n = 15–30/group before and n = 6/group after 16 weeks) (A), nose-to-anus body length (B), lean mass (C), fat mass (D), percent
adiposity (E), plasma leptin (F), overnight fasted (16 h) plasma triglycerides (G), daily food intake (n = 14–15/group, 14-week-old mice) (H), and liver triglyceride
content (n = 6/group for 24-week-old and n = 4/group for 8-week-old mice) (I).
(J–L) Comparison of LepRb-Stat3-KO and LepRb-Stat3-KO-Pten-OEmice in body weight (n = 12–35/group before and n = 10–28/group after 16 weeks) (J), lean
and fat mass (n = 8–23/group) (K), and liver triglyceride content (n = 6/group) (L).
Error bars and data points represent the mean ± SEM. *p < 0.05, **p < 0.01 versus control or as indicated; n.s., nonsignificant.
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DSTAT3 to a similar degree in controls and mutants, the ability of
leptin to induce the phosphorylation of AKT was severely
impaired in the mutant animals (Figure 4D). Total AKT and
STAT3 protein levels were similar between controls and mutants
(Figures S6A and S6B). This result indicates that LepRb-Pten-OE
mutant mice exhibit specific impairment of leptin-induced PI3K
signaling in the hypothalamus.Cell MAttenuated LepRb Neuron PI3K Signaling Causes
Increased Liver Triglycerides but Not Body Adiposity
LepRb-Pten-OE mice appear morphologically normal. Body
weight, body length, and lean and fat mass were indistinguish-
able between controls and mutants (Figures 5A–5E) examined
at 5, 8, and 24 weeks of age. Plasma leptin and triglyceride
levels were also similar (Figures 5F and 5G). The nonsignificantetabolism 14, 791–803, December 7, 2011 ª2011 Elsevier Inc. 797
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Central Leptin Resistance and Hepatic Steatosistrend toward lower body adiposity at 24 weeks of age could be
associated with a slight decrease in feeding (Figure 5H). Despite
lower food intake and a trend toward lower body adiposity, which
likelywould have led to reduced liver fat content, LepRb-Pten-OE
mice showed a significant increase in liver triglyceride levels
(Figure 5I).
Attenuated PI3K Signaling in LepRb Neurons Promotes
Hepatic Steatosis Independent of Leptin-Mediated
Stat3 Signaling
To evaluate potential crosstalk between PI3K and Stat3 sig-
naling in leptin target neurons, we generated mice defective
in Stat3 (LepRb-Stat3-[KO]), or defective in both Stat3 and
PI3K function (LepRb-Stat3-KO-Pten-OE) in LepRb neurons.
As expected, LepRb-Stat3-KO mice developed severe obesity.
LepRb-Stat3-KO-Pten-OE mice also developed obesity and to
the same extent as the LepRb-Stat3-knockout mice (Figures
5J and 5K), suggesting that the lack of body weight phenotype
in LepRb-Pten-OEmice is unlikely due to compensatory upregu-
lation of Stat3 signaling. This result also suggests that further
reduction of total leptin signaling, Stat3 and PI3K signaling
combined, does not cause more severe weight gain, supporting
the notion that moderate attenuation of PI3K signaling does not
have significant impact on body weight. Interestingly, despite
having similar adiposity, LepRb-Stat3-KO-Pten-OE mice ex-
hibited greater liver triglyceride levels compared to LepRb-
Stat3-KO mice (Figure 5L). Together, these results demonstrate
that attenuation of PI3K signaling in LepRb neurons promotes
hepatic steatosis independent from any effects on body weight
and adiposity.
Impairment of PI3K Signaling in LepRb Neurons Results
in Reduced Sympathetic Tone and Increased Lipogenic
Gene Expression in the Liver
Elevation of liver triglyceride levels in LepRb-Pten-OEmice could
be due to an increased supply of free fatty acids, increased de
novo lipogenesis, reduced b-oxidation, or reduced very low-
density lipoprotein (VLDL) secretion from the liver. No significant
differences in circulating NEFA or glucose were observed (Fig-
ures 6A and 6B). Plasma insulin levels were lower in LepRb-
Pten-OE mice (Figure 6C), but no significant difference in
insulin-stimulated PI3K signaling was observed in the mutant
liver (Figure 6D). Furthermore, insulin levels were similar in
LepRb-Stat3-KO (9.31 ± 0.99 ng/ml after a 4 h fast and 3.48 ±
0.40 ng/ml after a 16 h fast) and LepRb-Stat3-KO-Pten-OE
mice (10.70 ± 1.45 ng/ml after a 4 h fast and 3.45 ± 0.51 ng/ml
after a 16 h fast), despite higher liver triglyceride levels in the
latter genotype, suggesting that hepatic steatosis in these
animals is not related to plasma insulin levels. The release of
VLDL from the liver was determined by the plasma accumulation
of triglycerides after injection of lipoprotein lipase inhibitor
Triton WR-1339 in fasted mice, and no differences were
observed (Figure 6E). Two genes involved in b-oxidation, carni-
tine palmitoyltransferase 1 (Cpt1) and peroxisome proliferator-
activated receptor alpha (Ppara), did not change significantly
(Figure 6F). However, the mRNA expression of Acc, Fas, and
Scd1 increased in the livers of LepRb-Pten-OE mice, as did
FAS activity (Figures 6F and 6G). The hepatic mRNA expression
of these lipogenic genes also increased in LepRb-Stat3-KO-
RE
TR
A798 Cell Metabolism 14, 791–803, December 7, 2011 ª2011 ElsevierPten-OE mice when compared to similarly obese LepRb-
Stat3-KO mice (Figure S6E).
To examine whether increased liver triglyceride levels in the
mutant animals are associated with reduction of sympathetic
activity, we conducted a NE turnover assay. The liver NE content
was significantly lower at baseline and the turnover rate was
markedly reduced in the LepRb-Pten-OE mice compared with
that of the controls (Figures 6H and 6I). Together, these results
suggest that enhanced de novo lipogenic activity contributes
to elevated liver triglyceride content in the mutant mice, which
is associated with a reduction in the hepatic sympathetic tone.
Leptin’s Effects on Liver Sympathetic Activity and
Lipogenic Gene Expression, and Triglycerides Are
Blunted in LepRb-Pten-OE Mice
To evaluate the responsiveness of the LepRb-Pten-OE mutant
mice to leptin, we infused vehicle or leptin to control and
LepRb-Pten-OE mice via osmotic minipumps for 7 days. Mice
were weight-matched at the beginning of the experiment. Cen-
tral infusion of leptin caused similar reductions in body weight,
food intake, fat depot weight, blood glucose, and plasma insulin
levels in control and mutant mice (Figure 7A), despite the lower
baseline insulin levels in the mutants (aCSF-infused: controls
1.68 ± 0.13 ng/ml, mutants 1.22 ± 0.09 ng/ml, p < 0.05; leptin-
infused: controls 0.43 ± 0.09 ng/ml, mutants 0.26 ± 0.07 ng/ml,
p = 0.2). In contrast, although vehicle-treated mutant mice
showed greater liver triglyceride and Scd1, Acc, and Fas mRNA
levels (data not shown), leptin’s suppressive effect on these
parameterswas significantly impaired (Figures7Aand7B).More-
over, leptin infusion significantly increased liver NE levels in the
controls but was ineffective in the mutants (Figure 7C). These
results suggest that impairment of PI3K signaling in LepRb
neurons blunted leptin’s effects on liver sympathetic activity
and triglyceride levels.
DISCUSSION
Regulation of energy balance and hepatic lipid metabolism are
integral components of an overall regulatory program tomaintain
whole body metabolic homeostasis. The liver produces and
supplies triglycerides in the form of VLDL to adipose tissue for
storage and to muscle for oxidation, processes closely linked
to the body’s energy status. We show here that leptin acts in
the brain through PI3K to reduce hepatic liver triglyceride levels
via a mechanism independent of food intake and body weight,
and that attenuation of PI3K signaling in LepRb neurons pro-
motes hepatic steatosis independent of obesity. This suggests
that leptin regulates energy balance and hepatic lipid metabo-
lism via distinct signalingmechanisms. In support of our findings,
development of liver steatosis precedes the onset of obesity
upon short term consumption of a high fat diet (Samuel et al.,
2004), suggesting that regulation of hepatic liver metabolism
and body weight can be uncoupled. Furthermore, the observa-
tion that leptin-mediated PI3K, but not Stat3, signaling is im-
paired after short-term exposure to high-fat diet suggests that
disruption to leptin-mediated Stat3 and PI3K signaling can occur
via different mechanisms (Metlakunta et al., 2008).
The liver is innervated by sympathetic nerves (Yi et al., 2010).
By using transynaptic retrograde viral tracing, neurons in
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Figure 6. LepRb-Pten-OE Mice Show Reduced Hepatic Sympathetic Tone and Increased Lipogenic Gene Expression in the Liver
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(H) Disappearance of liver NE levels after a-MPT injection (n = 4–6/time point), with regression lines for each genotype.
(I) Liver NE turnover rate.
Error bars and data points represent the mean ± SEM. *p < 0.05, **p < 0.01 versus control.
Cell Metabolism
Central Leptin Resistance and Hepatic Steatosis
RE
TR
CT
EDmultiple sites of the brain, including many hypothalamic nuclei
and the nucleus of the solitary tract, are shown to project to
the liver, demonstrating that the brain can regulate liver function
via autonomic neuronal circuits (Stanley et al., 2010). Since
LepRb neurons are abundant in these brain regions (Leshan
et al., 2006; Scott et al., 2009), it is likely that coordinated leptinCell Msignaling in multiple brain regions is required for proper regula-
tion of hepatic lipid content. Leptin is known to activate the
sympathetic nervous system in rodents, primates, and humans
through increased catecholamine output (Buettner et al., 2008;
Rosenbaum et al., 2005; Satoh et al., 1999; Tang-Christensen
et al., 1999). We show here that chronic central leptin infusionetabolism 14, 791–803, December 7, 2011 ª2011 Elsevier Inc. 799
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Figure 7. Leptin’s Effects on Hepatic Sympathetic Tone, Lipogenic
Gene Expression, and Liver Triglycerides Are Blunted in LepRb-
Pten-OE Mice
Control and LepRb-Pten-OE mutant mice were implanted with cannulae
attached to osmotic minipumps delivering either vehicle or leptin for 7-days
(n = 4–5/group).
(A–C) Body weight, food intake, body adiposity, blood glucose, plasma insulin
and liver triglyceride concentrations (A), liver mRNA expression of Acc, Fas,
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value for each respective genotype.
Error bars and data points represent the mean ± SEM. *p < 0.05, **p < 0.01
versus control.
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via PI3K elevates liver sympathetic activity and that NE directly
exerts an effect on liver lipogenic gene expression.
Our study shows that leptin-mediated PI3K signaling acts to
reduce hepatic triglyceride levels by suppressing expression of
genes involved in de novo lipogenesis. Prieur and colleagues
have suggested that leptin regulates liver lipid metabolism,
including Scd1 mRNA expression, primarily through effects on
food intake (Prieur et al., 2008). However, other studies show
that leptin suppresses liver Scd1 expression to a much greater
extent than pair-fed animals (Cohen et al., 2002; Gallardo
et al., 2007), suggesting that the effects of leptin on food intake
cannot fully explain the hormone’s actions on liver triglyceride
metabolism. These discrepant results are likely due to differ-
ences in the method and duration of leptin treatment. In study
of Prieur et al., leptin was injected acutely twice daily via a
cannula for 3 days. In contrast, our study and that of Cohen
and Gallardo used osmotic minipumps, which allows constant
delivery of leptin at a steady rate for longer periods of time
(7–12 days). Prolonged treatment might be necessary to sepa-
rate the anorectic and other metabolic effects of leptin.
Although the presence of the LepRb in the liver has been sug-
gested, our study indicates that the increase in liver triglyceride
levels in LepRb-Pten-OE mice is attributed to impaired PI3K
signaling in the brain, not hepatocytes. Consistently, deletion
RE
TR800 Cell Metabolism 14, 791–803, December 7, 2011 ª2011 Elsevierof the leptin receptor gene from hepatocytes and other periph-
eral tissues does not alter energy balance or liver fat metabolism
(Cohen et al., 2001; Guo et al., 2007). It is interesting to note that
the increased liver triglyceride levels in LepRb-Pten-OEmice are
not accompanied by insulin resistance. Although hepatic steato-
sis is often associated with insulin resistance in obese in-
dividuals, a number of studies have indicated that these two
processes can be uncoupled under nonobese conditions (Bid-
dinger et al., 2008; Monetti et al., 2007). Genetic induction of
hepatic steatosis in the absence of any other metabolic dis-
turbance causes increased systemic insulin sensitivity via an
afferent liver-to-brain autonomic circuit (Uno et al., 2006). It
remains undetermined whether this autonomic circuit relays
the increased liver triglyceride content of LepRb-Pten-OE mice
to the brain and increases, in turn, systemic insulin sensitivity
that could account for lower plasma insulin levels despite normal
blood glucose concentrations in these mutant mice. Consistent
with this notion, we found that insulin sensitivity was enhanced
in the adipose tissue of LepRb-Pten-OE mice (Figures S6C
and S6D), although we cannot exclude the possibility that a
reciprocal pathway exists, by which liver triglyceride content
could be influenced indirectly by insulin actions in adipose
tissue.
Our transgenic model is distinct from gene targeting ap-
proaches that delete PI3K subunits, as they often alter the
expression of nontargeted isoforms causing compensatory
changes in kinase activities (Vanhaesebroeck et al., 2005). In
addition, deletion of only one allele of the PI3K subunit may not
impair PI3K activity if the deleted subunits are not limiting
(Foukas et al., 2006). In our model, components of the PI3K
protein complex are intact, but upregulation of PTEN impairs
the ability of leptin to stimulate PI3K signaling, causing cellular
leptin resistance. Although we cannot rule out the involvement
of a nonleptin mediated signal that also activates PI3K in LepRb
neurons, such as insulin, multiple lines of evidence indicate that
central leptin action underlies the phenotype of LepRb-Pten-OE
mice.
First, leptin and insulin exert distinct effects on the neuronal
activities of Pomc neurons, and that acute response to leptin
and insulin are largely segregated into distinct subpopulations
of Pomc neurons (Williams et al., 2010). Second, although acute
injection of insulin into the brain decreases feeding, chronic infu-
sion of insulin into the brain increases fat mass without apparent
effects on feeding (Koch et al., 2008) via dampened sympathetic
activity, increased lipogenesis, and inhibited lipolysis in adipose
tissue (Scherer et al., 2011). Consistently, we show that chronic
central infusion of insulin causes increased fat mass and liver
triglyceride levels without affecting food intake. Thus, chronic
central insulin and leptin action appear to exert opposite effects
on peripheral lipid metabolism. Our mutant phenotype closely
reflects downregulation of leptin function. The fact that LepRb-
Pten-OE mice do not show increased fat mass does not support
potential enhancement of central insulin sensitivity. Third, al-
though it is known that direct insulin action on the liver plays
a major role in the regulation of Scd1 gene expression, the inhib-
itory effect of leptin on liver Scd1 expression is independent of
circulating insulin levels or liver insulin receptor function (Bid-
dinger et al., 2006). This suggests that leptin and insulin regulate
liver lipid metabolism via distinct mechanisms. Consistent with
CT
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Athis notion, insulin-induced liver AKT phosphorylation is not
altered in LepRb-Pten-OE mice, although we cannot exclude
the possibility that other signaling pathways might be affected
in our mutant mice. Fourth, liver weight and triglyceride content
in ob/obmice increase before the onset of obesity (Knehans and
Romsos, 1983, and this study). In addition, while starvation
causes a dramatic increase in liver triglyceride levels in wild-
type mice, starvation of ob/ob mice does not result in hepatic
steatosis but, rather, a decrease in liver triglyceride levels
(Salmon and Hems, 1973). Collectively these findings support
our notion that the regulation of liver triglyceride levels requires
intact leptin function.
Buettner and colleagues have reported that leptin acts in the
brain to suppress lipogenesis in white adipose tissue by activa-
tion of sympathetic outflow (Buettner et al., 2008). We also
examined lipogenic gene expression in white adipose tissue
upon central infusion of leptin. Consistently, we show that
central infusion of leptin caused elevation of norephinephrine
content and decreased expression of Acc, Fas, and Scd1 in
white adipose tissue depots (Figures S7A and S7B). Thus,
acute central leptin infusion may activate sympathetic nervous
system in both liver and white adipose tissues to inhibit lipogen-
esis. This notion is supported by anatomical evidence that
common neurons in the hypothalamus and brain stem are
found in the descending neuronal cascades that innervate liver
and adipose tissue (Stanley et al., 2010). It is interesting to note
that chronic attenuation of PI3K in leptin receptor-expressing
cells causes hepatic steatosis without affecting body adiposity
(this study). It is possible that sympathetic regulation of hepatic
lipid metabolism is more sensitive to perturbations of central
leptin signaling or that redundant mechanisms exist in white
adipose tissue to compensate for the attenuation of leptin sig-
naling. It may further suggest that a moderate degree of leptin
resistance could manifest as hepatic steatosis without causing
obesity.
In common obesity, such as diet-induced obesity, over-
consumption of a palatable diet induces a number of cellular
changes that diminish the ability of leptin to activate signaling
pathways in its target neurons, marking the onset of cellular
leptin resistance for these signaling pathways (Myers et al.,
2010). Leptin resistance impairs the ability of leptin to negatively
influence food intake and energy storage, sustaining and aggra-
vating the metabolic derangements in diet-induced obesity.
Impairment of leptin-stimulated PI3K signaling is one of the early
signaling defects associated with cellular leptin resistance,
occurring before a reduction of leptin-mediated Stat3 signaling
can be detected (Metlakunta et al., 2008). This suggests that
impairment of various leptin signaling pathways could be gov-
erned by distinct mechanisms. Although increased feeding and
body adiposity are commonly considered the primary outcomes
of leptin resistance, with hepatic steatosis suggested as a
secondary consequence of obesity, our results suggest that a
specific form of hypothalamic leptin resistance, marked by
impaired leptin-induced PI3K signaling, manifests as hepatic
steatosis independent of hyperphagia and obesity. With over
30% of the Western population suffering from NAFLD (Browning
et al., 2004), our study provides mechanistic insight into the
development of hepatic steatosis and paves the way for future
therapeutic treatment of fatty liver disease.
RE
TRCell MEXPERIMENTAL PROCEDURES
Generation of Mice with Cre-Dependent Pten Overexpression
Mice with Floxed-Stop-Tg.Pten were generated using a similar strategy as
described previously (Reed et al., 2010). Briefly, a DNA fragment containing
the cytomegalovirus (CMV) promoter was released from plasmid PHMCMV5
and subcloned into the BamHI site of the pDE1sp1A vector. Full-length mouse
Pten cDNA was placed behind a loxP-flanked polyadenylation cassette
(4xpA; floxed stop cassette). The resulting fragment was subcloned into the
pDE1sp1A downstream of the CMV promoter. A linear 10.5 kb DNA fragment
containing CMV-floxed-stop-Pten-polyA sequences was purified andmicroin-
jected into fertilized eggs from C57BL6/J donors.
Mouse Genetics
To generate mice with Pten overexpressed in specific neuronal populations,
heterozygous Floxed-Stop-Tg.Pten mice were crossed with mice heterozy-
gous for either Tg.Nestin-Cre (Jackson Laboratory) or Tg.LepRb-Cre (Leshan
et al., 2006). LepRb-Stat3-KO and LepRb-Stat3-KO-Pten-OE mice were
generated by introduction of floxed-Stat3 alleles (Takeda et al., 1998).
Controls for LepRb-Pten-OE were comprised of +/+;+/+, +/+;Tg.Pten /+ and
Tg.LepRb-Cre/+;+/+ genotypes. Controls for LepRb-Stat3-KO/LepRb-
Stat3-KO-Pten-OE mice comprised Stat3fl/+, Stat3fl/fl, Tg.Pten/+, Stat3fl/+, or
Tg.Pten,Stat3fl/fl genotypes. Because we observed no differences between
different control genotypes, we pooled them for analysis. C57BL/6J mice
(JAX) were used for most infusion studies. Mice were group-housed in a path-
ogen-free, temperature- (22C), humidity-, and light- (0700 h–1900 h lights on)
controlled environment with ad libitum chow (Purina mouse diet 5058) and
water access. All procedures were approved by the University of California
San Francisco Institutional Animal Care and Use Committee.
Intracerebroventricular Infusion
Anesthetized mice were mounted onto a stereotaxic apparatus (Model
1900; David Kopf Instruments) and implanted with an Alzet steel guide
cannula (Durect) into the right lateral ventricle (anteroposterior, 0.3 mm;
lateral, 1.0 mm; and dorsoventral, 2.5 mm below the skull, relative to
Bregma) attached to an osmotic minipump (Alzet Model 2006, Durect). Mini-
pumps and tubing was filled with vehicle (aCSF; 13% DMSO + 87% aCSF
for Figure 3), leptin (4 mg/day), insulin (0.2 mU/day Novolin R, Novo Nordisk
Inc), LY94002 (2.4 mg/day, Calbiochem), or leptin and LY294002, as appro-
priate. For single i.c.v. injections, a 2.5 mm guide cannula (Plastics One) was
implanted into the right lateral ventricle; 1 ml of aCSF or leptin (2 mg) was infused
at 10 nl/s via a 2.7 mm injector (Plastics One). Correct placement was verified
by a robust drinking response to angiotensin II (0.1mg/ml, Sigma) and by post-
mortem examination.
Norepinephrine Turnover Assay
NE turnover was calculated by the disappearance of liver NE level over time
after administration of a-methyl-p-tyrosine (a-MPT) to block NE biosynthesis,
as previously described (Brodie et al., 1966). Mice were deprived of food and
injected with a-MPT (250 mg/kg in saline i.p.); after 30 min, a subset of mice
(n = 6) was killed by cervical dislocation and tissues were collected for NE turn-
over rate calculations (Figure 2). The remainingmice received an i.c.v. injection
of aCSF (n = 6) or leptin (n = 6) (2 mg; Rahmouni et al., 2003); tissues were
collected after 3.5 h. Figure 6 shows that 20–24-week-old mice received an
injection of a-MPT (250 mg/kg i.p.); a subset of these mice (n = 4–6/group)
were killed by cervical dislocation immediately afterwards (0 h). Another subset
(n = 4–6/group) was killed 4 h after injection and a third subset (n = 4–6/group)
received a second i.p. injection of a-MPT (125 mg/kg i.p.) 4 h after the first and
were killed 4 h later (8 h time point).
Western Blotting
Twelve-week old mice received an injection of saline (10 ml/kg) or leptin
(3 mg/kg); hypothalami were microdissected after 45 min. In different experi-
ments, 8-week-old mice were fasted overnight and then given an i.p. injection
of saline (10 ml/kg) or insulin (2 U/kg or 5 U/kg, Novolin R, Novo Nordisk Inc.,
Princeton, NJ); samples were collected 15 min later. SDS-PAGE and western
blotting were performed as previously described (Reed et al., 2010) using stan-
dard procedures. The primary antibodies used included PTEN, pAKTser473,
CT
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Central Leptin Resistance and Hepatic SteatosispAKTthr308, AKT, pSTAT3tyr705, STAT3 (all Cell Signaling), ACC, pACCser79
(both Upstate), pERKtyr204, ERK or GAPDH (all Santa Cruz Biotechnology).
Hepatic Triglyceride Secretion
Mice were fasted overnight and then injected i.p. with Triton WR-1339
(500 mg/kg, Sigma; Millar et al., 2005). Blood was collected prior to and
2, 4, and 6 h after injection.
Body Composition
Lean and fat mass was determined using dual-energy X-ray absorptiometry as
previously described (Reed et al., 2010). For fat depot weight, the mesenteric,
perirenal, epididymal, scapular, and inguinal white adipose tissue depots were
removed and weights were summed.
Liver Explant Preparation
Liver slices 1 mm thick (50 mg) from 6-week-old C57bl/6 male mice were
preincubated for 2 h in Krebs-Ringer bicarbonate buffer pH 7.4 at 37C in a
humidified atmosphere saturated with 95% O2–5% CO2; buffer was replaced
after 1 and 1.5 h. Slices were then incubated for 2 h in buffer containing NE-HCl
(Sigma) or no drug, after which tissue was processed for RT-PCR analyses.
Biochemical Assays
Plasma insulin, NE, and leptin levels were measured using ELISA kits (Alpco
Inc., Salem, NH; Crystal Chem, Downers Grove, IL), blood glucose was
measured using a Freestyle glucometer (Abbott Diabetes Care), and plasma
NEFA and triglycerides were measured using colorimetric assays (Wako,
Sigma, respectively). Liver triglycerides were extracted using the Folch
method (Folch et al., 1957), quantified by colorimetric assay, and expressed
per mg DNA. Tissue NE concentrations were determined by homogenizing
the tissue in 0.01 N HCl containing 1 mM EDTA and 4 mM sodium metabisul-
fite, followed by extraction and quantification using a NE ELISA (Alpco Diag-
nostics, Salem, NH), with data expressed per mg or g wet tissue weight. Liver
FAS enzymatic activity was determined by the method of Linn (Linn, 1981) and
was standardized per mg DNA.
Quantitative RT-PCR
RNA was extracted, reverse-transcribed, and then PCR-amplified (7900HT
Fast Real-Time PCR System) using specific TaqMan gene expression
assays and Universal PCR Master Mix (Applied Biosystems); b-actin was
used to normalize expression.
Statistics
All data are normally distributed (Shapiro Wilks test). Data from two groups
were compared using 2-tailed Student’s t tests. For more than two groups,
either one- or two-way ANOVA was used, as appropriate, followed by post
hoc tests. For growth curves, repeated-measures ANOVA was used. Correla-
tions were conducted using Pearson’s correlation. Data are expressed as
mean ± SEM. Significance was defined at p < 0.05.
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